Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 205,174,208 papers from all fields of science
Search
Sign In
Create Free Account
APC 8015
Known as:
APC-8015
, APC8015
, APC8015 Vaccine
A cell-based vaccine composed of autologous antigen-presenting peripheral blood mononuclear cells (enriched for a dendritic cell fraction) that have…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
3 relations
Dendritic Cells
Provenge
Broader (1)
sipuleucel-T
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Review
2011
Review
2011
Vaccine therapy with sipuleucel-T (Provenge) for prostate cancer.
E. Thara
,
T. Dorff
,
J. Pinski
,
D. Quinn
Maturitas
2011
Corpus ID: 25420646
Review
2008
Review
2008
Sipuleucel-T: A Vaccine for Metastatic, Asymptomatic, Androgen-Independent Prostate Cancer
P. H. Patel
,
D. R. Kockler
The Annals of pharmacotherapy
2008
Corpus ID: 21210840
Objective: To review the design, efficacy, safety, dosing, therapeutic, and pharmacoeconomic considerations of sipuleucel-T, an…
Expand
Review
2007
Review
2007
Immunotherapy for prostate cancer using antigen-loaded antigen-presenting cells: APC8015 (Provenge®)
A. Harzstark
,
E. Small
Expert opinion on biological therapy
2007
Corpus ID: 29009607
Dendritic cells are deficient both in number and function in patients with cancer. Loaded dendritic cell therapies aim to…
Expand
Highly Cited
2006
Highly Cited
2006
Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer.
E. Small
,
P. Schellhammer
,
+6 authors
R. Hershberg
Journal of clinical oncology : official journal…
2006
Corpus ID: 7333925
PURPOSE Sipuleucel-T (APC8015) is an investigational immunotherapy product designed to stimulate T-cell immunity against…
Expand
Highly Cited
2006
Highly Cited
2006
Combination immunotherapy with prostatic acid phosphatase pulsed antigen‐presenting cells (provenge) plus bevacizumab in patients with serologic progression of prostate cancer after definitive local…
B. Rini
,
V. Weinberg
,
L. Fong
,
S. Conry
,
R. Hershberg
,
E. Small
Cancer
2006
Corpus ID: 25676266
APC8015 (sipuleucel‐T) is a cellular prostate cancer vaccine containing autologous antigen‐presenting cells (APC) loaded with…
Expand
Review
2006
Review
2006
Sipuleucel-T (APC8015) for prostate cancer
R. So-Rosillo
,
E. Small
Expert review of anticancer therapy
2006
Corpus ID: 40114179
Sipuleucel-T (Provenge®; APC8015; Dendreon Corp, WA, USA) is a novel immunotherapeutic cellular product, which includes…
Expand
Highly Cited
2005
Highly Cited
2005
Antigen-presenting cells 8015 (Provenge) in patients with androgen-dependent, biochemically relapsed prostate cancer.
G. Beinart
,
B. Rini
,
V. Weinberg
,
E. Small
Clinical prostate cancer
2005
Corpus ID: 22685093
BACKGROUND Antigen-presenting cells 8015 (APC8015; Provenge) is an immunotherapeutic product designed to initiate a T-cell…
Expand
Highly Cited
2004
Highly Cited
2004
Immunotherapy (APC8015, Provenge®) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen‐independent prostate cancer: A phase 2 trial
P. Burch
,
G. Croghan
,
+6 authors
S. Vuk-Pavlović
The Prostate
2004
Corpus ID: 34924100
Prostate cancer is the most commonly diagnosed malignancy in American men, yet treatment of its metastatic androgen‐independent…
Expand
Review
2002
Review
2002
Technology evaluation: APC-8015, Dendreon.
B. Rini
Current opinion in molecular therapeutics
2002
Corpus ID: 43594022
Dendreon (formerly Activated Cell Therapy), in association with the Mayo Clinic, is developing the dendritic cell therapy APC…
Expand
Highly Cited
2000
Highly Cited
2000
Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer.
P. Burch
,
J. Breen
,
+12 authors
S. Vuk-Pavlović
Clinical cancer research : an official journal of…
2000
Corpus ID: 5941578
We attempted to induce therapeutic immunity against prostate-derived tissues in patients suffering from progressive hormone…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
,
Terms of Service
, and
Dataset License
ACCEPT & CONTINUE